锰苯甲酸卟啉干预活性氧在小肝移植物缺血再灌注损伤中的作用及其意义  

Protective effect of MnTBAP on small for size graft ischemia-reperfusion injury in liver transplantation rats

作　　者：崔一尧[1] 钱建民[1] 芮晓晖[1] 王乾伟[1] 马震宇[1] 

机构地区：[1]复旦大学附属华山医院肝胆外科,上海200040

出　　处：《中华实验外科杂志》2009年第2期194-196,共3页Chinese Journal of Experimental Surgery

基　　金：上海市自然科学基金资助项目（07ZR14017）

摘　　要：目的观察锰苯甲酸卟啉（MnTBAP）对SD大鼠小肝移植物模型缺血再灌注损伤的治疗及保护作用。方法采用二袖套法建立供肝／标准肝体积比（GV／SV）≤30％的小肝移植物大鼠模型，将大鼠随机分为A：假手术组（n=24），B：对照组（n=24），C：MnTBAP治疗组（n=24），于复流后3、6、12、24h各取6只处死取材，检测各组大鼠肝组织中肿瘤坏死因子（TNF）-α mRNA表达、髓过氧化物酶（MPO）、丙二醛（MDA）、肝功能指标和肝细胞凋亡间的状态。结果与假手术组比较，对照组肝组织TNF-α mRNA及MDA、MPO含量显著升高（P〈0．01），肝丙氨酸转氨酶（ALT）活性显著升高（P〈0．01），肝细胞凋亡明显增多（P〈0．01）；而MnTBAP治疗组的肝组织MDA、MPO含量较对照组显著降低（P〈0．05），肝细胞凋亡减少，且在术后6、12、24h，肝TNF—α mRNA表达均下降（P〈0．05），血清ALT水平也明显降低（P〈0．01）。结论MnTBAP可以抑制中性粒细胞的呼吸爆发，降低肝组织TNF-αmRNA表达、减轻细胞膜损伤程度，对缺血肝损伤有良好的保护作用。Objective To study the protective effect of MnTBAP on small for size graft ischemia- reperfusion injury in liver transplantation rats. Methods The models of liver transplantation with graft volume/standard liver volume （GV/SLV） ≤30% were created by two-cuff method in SD rats. The rats were randomly divided into sham operation group, untreated group, and model group treated by MnTBAP. The expression of TNF-α mRNA and the levels of myeloperoxiase （ MPO）, malondialdehyde （MDA） were measured as well as alanine aminotransferase （ALT） levels at 3rd,6th, 12th,and 24th h after reperfusion determined. Results Compared with the sham operation group, the expression of TNF-α mRNA, and the levels of MDA,MPO and ALT in the grafts were significantly higher （ P 〈 O. 01 ） in untreated group. In model group treated by MnTBAP,the expression of TNF-α mRNA and the levels of MDA,MPO and ALT were significantly lower than in untreated group （ P 〈 0.05 or P 〈 0.01 ）. Conclusion Protective effect of MnTBAP on liver graft ischemia-reperfusion injury in rats was remarkable by reducing the TNF-α mRNA expression and inhibiting the activity of ROS. thus lessening the level of MDA.

关 键 词：肝移植 MnTBAP 缺血 再灌注损伤 

分 类 号：R657.3[医药卫生—外科学] R698.2[医药卫生—临床医学]